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Endothelin-1 (ET-1)-converting enzyme (ECE) activity in the human serum lipoprotein fraction was studied using a sensitive nzyme immunoassay 
and reverse-phase high performance liquid chromatography. The ECE activity of cleaving synthetic human big ET-I into ET-l by the serum 
lipoprotein fraction was about 14-times greater than that by whole serum, and the activity was closely associated with lipoprotein itself. The 
lipoprotein ECE activity, which was optimal at pH 7.0, was inhibited by EDTA, o-phenanthroline, phosphoramidon, thiorphan, phenylmethane- 
sulfonyl fluoride and chymostatin, but not by cysteine or aspartic proteinase inhibitors, suggesting metalloproteinase- and chymotrypsin-like 
properties. These results suggest hat the serum lipoprotein ECE may be involved in the processing of big ET-l to ET-l in the circulatory system. 
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1. INTRODUCTION 
Endothelin-1 (ET-l) is a potent vasoconstrictor pep- 
tide with 21 amino acid residues originally isolated from 
the culture supernatant of porcine aortic endothelial 
cells (ECs) [l]. Human ET-l is generated from a 3% 
residue intermediate form, termed big ET- 1, through a 
specific cleavage at the Trp*‘-Val** bond by a putative 
ET-converting enzyme(s) (ECE). Since the vasocon- 
strictor activity of big ET-l is much lower than that of 
ET-l [2], the conversion of big ET-l to ET-l in vivo is 
essential for physiological functions of ET-l. 
aimed at elucidating whether human serum has any 
ECE activities, and to characterize serum components 
responsible for ECE activity. 
2. MATERIALS AND METHODS 
2.1. Materials 
It was initially suggested that ECE could be a chy- 
motrypsin-like proteinase(s). Indeed, chymotrypsin has 
been shown to generate ET-1 from big ET-l [3]. Re- 
cently, several groups have reported that ECE present 
in cultured ECs [4,5] and vascular smooth muscle cells 
[6] was a phosphoramidon-sensitive n utral metallopro- 
teinase(s). It has been shown that intravenous injection 
of big ET-l to anesthetized rats produced a pressor 
effect similar to ET-l, and this effect was inhibitable 
with phosphoramidon [7-lo]. These findings suggest 
that phosphoramidon-sensitive ECE is responsible for 
the conversion of big ET-l to ET-l in vivo, however, it 
remains unknown whether conversion of big ET-l to 
ET-l in vivo is due to membrane-bound enzyme(s) or 
circulating one(s). Therefore, the present study was 
Synthetic ET-I (l-21), ET-2 (l-21) ET-3 (l-21), human big ET-l 
(l-38), human big ET-2 (l-37), human big ET-2 (l-38) and human 
big ET-3 (141, amide) were purchased from Peptide Institute Inc. 
(Osaka, Japan), sandwich enzyme immunoassay (EIA) kits for ET-l/ 
ET-2 and for ET-3 from IBL Co. (Gunma, Japan), dextran sulphate 
(molecular weight 500,000 Da) from WAKO Pure Chemical Co. 
(Osaka, Japan), EDTA. phosphoramidon, chymostatin and E-64 from 
Boehringer-Mannheim GmbH (Mannheim, Germany), thiorphan, 
pepstatin A and captopril from Sigma Chemical Co. (St. Louis, USA), 
phenylmethanesulfonyl fluoride (PMSF) and N-methylmaleimide 
from Nacalai Tesque Inc. (Kyoto, Japan), l,lO-phenanthroline (o- 
phenanthroline) from Merck Co. (Rahway, USA), Sep-Pak C,, car- 
tridge from Waters Assoc. (Milford, USA), NAP-5 column, heparin- 
Sepharose CLdB and blue-Sepharose CL-6B from Pharmacia Co. 
(Uppsala, Sweden), and goat anti-lipoprotein (a +p) antiserum from 
Nordic Immunological Laboratories (Tilburg, The Netherlands). 
2.2. Isolatron of lipoprotein fraction 
Serum was obtained from 6 healthy male donors 4 h after a meal, 
and a density fraction up to 1.210 g/ml of serum was prepared by 
ultracentrifugation. Briefly, the solvent density of serum was adjusted 
to 1.210 g/ml by adding solid KBr. After adjustmg the pH to 7.0, the 
solution was centrifuged at 100,000 x g for 20 h at 4°C. The lipopro- 
tein fraction was removed and dialysed against 150 mM NaCI/lO mM 
Tris-HCI buffer (pH 7.0). Determination of protein concentration was 
performed by the modified method of Lowry et al. 
Correspondence address: T. Ohwaki, Pharmaceutical Research Center, 
Nisshin Flour Milling Co. Ltd., 5-3-l Tsurugaoka, Ohi-machi, Iruma- 
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2.3. Precipitation of lipoprotein 
Abbreviations: ET-l, endothelin-I; big ET-l, big endothelin-1; IR-ET-l, 
immunoreactive ndothelin-1; ECE, endothelin converting enzyme. 
A solution of 10% dextran sulfate and/or 1 M MnCl, was added to 
0.5 ml serum lipoprotein fraction so as to provide final concentrations 
of 0.65% and 0.2 M, respectively. After leaving at room temperature 
for 2 h, the lipoprotein precipitate was removed by centrifugation at 
Published by Elsevier Science Publishers B. V. 165 
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Fig. 1. Conversion of big ET-l to ET-l by human serum and lipopro- 
tein fraction. Dialysed lipoprotein fraction (0) or dialysed serum (0) 
(OS ml) was incubated with big ET-l (0.5 nmol) at 37°C for the 
indicated times. 
20,000 x g for 30 min at 4°C. The resulting supernatant (0.5 ml) was 
subjected to a NAP-5 column equilibrated with 150 mM NaCl/lO mM 
Tris-HCl buffer (pH 7.0), and eluted with the same buffer. 
2.4. Measurement of ECE activity 
Big ET-1 (1 nmol/ml) was incubated with the lipoprotein fraction 
in 150 mM NaCI/lO mM Tris-HCl buffer (pH 7.0) at 37°C for 6 h. 
The reaction was stopped by adding of 2 mM EDTA. Immunoreactive 
(IR) ET-l generated uring incubation was measured. IR-ET-l gener- 
ated by the whole serum was extracted with a Sep-Pak Cl8 cartridge 
as described [I 11. 
2.5. Sandwich enzyme immunoassay (EIA) 
EIA for ET-l/ET-2 was performed by a sandwich EIA kit using 
anti-ET-l (15-21) (rabbit IgG) and anti-ET-l (rabbit IgG Fab’-horse- 
radish peroxidase labeled). EIA for ET-3 was performed by a sand- 
wich EIA kit using anti-ET-l (15-21) (rabbit IgG) and anti-ET-3 
(rabbit IgG Fab’-horseradish peroxidase labeled). These assay kits are 
sensitive enough to detect as little as 10 pg/ml; the cross-reactivities 
of the antibodies with big EG-1, big ET-2 or big ET-3 in each EIA 
were less than 0.1%. 
2.6. Reverse-phase high performance liquid rhromatography (RP- 
HPLC) 
RP-HPLC was performed as described [12] using a Capcell-Pak 
C,,-SGl20 column (4.6 x 250 mm. Shiseido, Tokyo, Japan). Fractions 
were evaporated and assayed for IR-ET-l. 
3. RESULTS AND DISCUSSION 
As shown in Fig. 1, incubation of synthetic human 
big ET-l with human serum and the lipoprotein fraction 
(density fraction cl.210 g/ml) resulted in a time-de- 
pendent increase in IR-ET-l, which reached a plateau 
after 9 h. The amounts of IR-ET-l generated by the 
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lipoprotein fraction were about 14-fold greater than 
those by the serum. Characterization of IR-ET-l mate- 
rial in the reaction mixture of big ET- 1 with the lipopro- 
tein fraction by RP-HPLC revealed that a major peak 
of IR-ET-l eluted at the position of synthetic ET-l, 
while a minor peak corresponding to human big ET-l 
was also observed (Fig. 2). These data suggest hat the 
ECE activity in human serum was mainly concentrated 
in the lipoprotein fraction. 
To ascertain whether lipoprotein itself had any ECE 
activities, serum lipoprotein was removed by precipita- 
tion with dextran sulphate and MnCI, to prepare lipo- 
protein-free supernatant, while lipoprotein-containing 
supernatant was obtained by adding either one of them 
to the lipoprotein fraction [13]. Human big ET-l was 
incubated with the lipoprotein-containing and the lipo- 
protein-free supernatant and the IR-ET-l generated 
was measured by a sandwich EIA for ET- 1. As shown 
in Fig. 3, the ECE activity was negligible in the lipopro- 
tein-free supernatant, whereas the ECE activity re- 
mained unchanged in the lipoprotein-containing super- 
natant after treatment with either dextran sulphate or 
MnCl, alone. We also found that the ECE activity of 
the lipoprotein fraction was adsorbed on heparin- 
Sepharose CL-6B, blue-Sepharose CL-6B and anti- 
human lipoprotein (a + p) IgG-Sepharose 4B (data not 
shown), indicating that the ECE activity in the lipopro- 
tein fraction is closely associated with lipoprotein itself. 
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Fig. 2. Reverse-phase HPLC profile of lmmunoreactive (IR)-ET-l 
after incubation of big ET-l with serum lipoprotein fraction. The 
lipoprotein fraction (11.6 mg protein) was incubated with big ET-l (1 
nmol) for 6 h at 37°C. Amounts ofIR-ET-l in each fraction are shown 
by filled circles and the gradient of acetonitrile is shown by a dotted 
line. Arrows indicate the elution positions of synthetic human big 
ET-1 (1) and ET-l (2). 
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Fig. 3. The ECE activity of lipoprotein-containing and lipoprotein- 
free supernatant. The lipoprotein-containing supematant after treat- 
ment with either dextran sulphate or MnCl,, and the lipoprotein-free 
supematant after precipitation with dextran sulphate and MnCl, (200 
~1) were incubated with big ET-1 (0.2 nmol) for 6 h at 37°C. Each 
column represents the mean of two experiments. 
We next examined enzymatic properties of the ECE 
activity of serum lipoprotein. The pH profile of the 
lipoprotein ECE activity is shown in Fig. 4. The effect 
of various proteinase inhibitors on the lipoprotein ECE 
activity were studied (Table I). The lipoprotein ECE 
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Fig. 4. The pH profile of the ECE activity of serum lipoprotein. The 
lipoprotein fraction (0.37 mg protein) was incubated big ET-1 (0.2 
nmol) in 50 mM of different buffers for 6 h at 37°C. Buffers used were 
sodium-acetate, pH 3.5-6.0 (o), PIPES-NaOH, pH 6.67.0 (o), Tris- 
HCl, pH 7.0-9.0 (0) and sodium bicarbonate, pH 9.&10.0 (m). Each 
point is the mean of two experiments. 
activity was inhibited by EDTA, o-phenanthroline and 
metalloproteinase inhibitors (phosphoramidon, thior- 
phan) and serine proteinase inhibitors (PMSF, chy- 
mostatin). Captopril had a slight inhibitory effect, but 
cysteine proteinase inhibitors (N-ethylmaleimide, E-64) 
or aspartic proteinase inhibitor (pepstatin A) had no 
effect. 
Our data suggest hat the lipoprotein ECE activity 
was sensitive not only to metalloproteinase inhibitors 
but also to serine proteinase inhibitors. Recently, Wypij 
et al. [14] reported that there were two pertinent ECE 
activities, a chymotrypsin-like proteinase (chymase) 
and a phosphoramidon-sensitive metalloproteinase, in 
the lung particulate fraction of the rat. Since the lipo- 
protein fraction is composed of heterogeneous mole- 
cules, it seems possible that the ECE in the lipoprotein 
fraction may consist of a mixture of metalloproteinase- 
and chymotrypsin-like proteinase. Alternatively, the 
ECE in the lipoprotein fraction may be a single enzyme 
with both metalloproteinase- and chymotrypsin-like 
proteinase properties. It should be noted that human 
apolipoprotein (a) contains a plasminogen-like serine 
proteinase domain within the molecule [15], the prote- 
olytic activity of which is inhibitable with PMSF, but 
not with o-phenanthroline [ 161. 
The lipoprotein ECE did not significantly cleave big 
ET-2 (l-37) or big ET-2 (l-38) into ET-2, as measured 
by EIA for ET-l/ET-2, whereas its converting activity 
for big ET-3 as measured by EIA for ET-3 was one- 
third as much as that for big ET-l (data not shown). 
Although the amino acid sequence of the cleavage site 
(Trp2’-Va122) of big ET-2 (l-37) and big ET-2 (l-38) is 
identical to that of big ET-l, the possible cleavage site 
(Trp2’-Ile22) of big ET-3 is different from that of big 
ET-l and big ET-2. However, the C-terminal region of 
big ET-3 (G*8-Ser39-Phe40-A&‘) is very similar to that 
of big ET-l (GlvxSer35-Pro36-ArJS37). It is possible to - 
Table I 
Effects of various proteinase inhibitors on ECE activity of serum 
lipoprotein 
Inhibitor Concentration (mM) Inhibition (%a) 
EDTA 1.0 100 
o-Phenanthroline 0.1 50 
0.5 98 
Phosphoramidon 0.1 96 
Thiorphan 0.1 95 
PMSF 0.1 29 
1.0 84 
Chymostatin 0.01 79 
E-64 0.1 0 
Captopril 0.1 32 
N-Ethylmaleimide 1.0 4 
Pepstatin A 0.01 0 
The lipoprotein fraction (0.28 mg protein) was incubated with big 
ET-l (0.2 nmol) for 6 h at 37°C. The amount of IR-ET-1 generated 
during 6 h in the absence of proteinase inhibitors was 1.39 pmol. 
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speculate that the C-terminal region (3437) of big ET-l 
may be the recognition site by the lipoprotein ECE. A 
similar finding has been reported on the phosphorami- 
don-sensitive ECE from bovine ECs [ 171, showing that 
the C-terminal region (Gly32-Leu33-Gly34-Ser3s-Pro36- 
Arg3’) of big ET-l is important for conversion by the 
endothelial ECE. 
[4] Okada, K., Miyazaki, Y., Takada, J., Matsuyama, K., Yamaki, 
T. and Yano, M. (1990) Biochem. Biophys. Res. Commun. 171, 
1192-1198. 
Recently, it has been reported that patients with ath- 
erosclerosis had raised plasma IR-ET-1 levels [ 181, and 
that plasma IR-ET-1 levels showed positive correlation 
with the extent of the atherosclerotic vascular lesions 
[19]. Furthermore, it has been reported that the plasma 
IR-ET-1 concentration showed positive correlation 
with plasma total cholesterol evels, and administration 
of clinofibrate reduced plasma IR-ET-1 levels in hyper- 
cholesterolemic rat [20]. Therefore, it is possible to pos- 
tulate that the enhanced activity of the lipoprotein ECE 
in hypercholesterolemia may increase circulating IR- 
ET-l levels. The question as to which fraction of the 
serum lipoprotein has ECE activity, and whether the 
lipoprotein ECE is involved in the development and/or 
progression of atherosclerosis, need to be answered. 
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